Preliminary study of protein expression profiling of PCOS on different state

National Medical Journal of China

Volumn 88, Issue 1, 2008, Pages 7-11

  Zhao, Shu Yun ^a   Qiao, Jie ^b   Li, Mei Zhi ^b   Zhang, Xiao Wei ^b   Yu, Jie Kai ^b   Li, Rong ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b NONE

Author keywords

Insulin resistance; Polycystic ovary syndrome; Protein profile

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; CHINA; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SUPPORT VECTOR MACHINE;

BLOOD PROTEINS; FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 41549119980     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab, 1998,83:3078-3082.
2. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am, 2005,34:677-705.
3. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod, 2002,17:2858-2864.
4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 2004,81: 19-25.
5. Issaq HJ, Veenstra TD, Conrads TP, et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun, 2002, 292: 587-592.
6. Chinese source.
7. Lee Y, Lee CK. Classification of multiple cancer types by multicategory support vector machines using gene expression data. Bioinformatics, 2003,19:1132-1139.
8. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril, 2002,77:1095-1105.
9. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature, 2003,425:905.
10. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol, 2004,15:24-30.
11. Dayal B, Ertel NH. ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA- I and apoA- II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res, 2002,1:375-380.
12. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin Chim Acta, 2005,357:113-122.
13. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359: 572-577.
14. Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol, 1999,83:3F-12F.
15. Shachter NS. Apolipoproteins C- I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol, 2001, 12:297-304.
16. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab, 2003,14:365-370.